nivolumab,ipilimumab,cabozantinib
bms,exelixis
['nivolumab', 'ipi/', '/ipi', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', ' ipi ', 'cosmic313', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ipilimumab', 'cabo ', 'nivo', 'cosmic-313', 'bristol', 'exelixis']
cosmic313 cabo/ipi/nivo vs ipi/nivo in 1st line rcc. fu &amp; numbers show continued strong pfs signal:hr 0.74.exploratory analysis show benefit for triplet mainly in intermediate risk .this is not due to drug exposure. maybe vegf treatment active in poor risk #gu23 
Interested in Urology Cancers, biomarkers and drug development.